Granules India targets ₹2,000 crore CAPEX for growth
after close1 source ↓machine-written, see hownot a recommendation
- organic capital expenditure
- ₹2,000 crore
- in revenue
- $100 million
- of US exclusivity
- 180 days
Granules India plans a ₹2,000 crore organic capital expenditure over the next 3-4 years to transition from bulk generics to high-value formulations. This includes a peptide CDMO arm aiming for $100 million in revenue within five years and a First-to-File challenge for Ruxolitinib, potentially securing 180 days of US exclusivity.
This strategic shift may enhance Granules India's market position and revenue potential, appealing to investors looking for growth in the pharmaceutical sector.
Not investment advice. For informational purposes only.